查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
医疗用食品全球市场-各用途，各类型，各销售管道，各地区展望，竞争策略，至2030年的各市场区隔预测
市场调查报告书
商品编码
1110908

医疗用食品全球市场-各用途，各类型，各销售管道，各地区展望，竞争策略，至2030年的各市场区隔预测

Global Medical Foods Market- By Application, By Type, By Sales Channel -Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 249 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球医疗用食品市场规模，预计今后以5.5％的年复合成长率扩大，至2030年达到343亿2,000万美元。

本报告提供全球医疗用食品市场相关调查，市场概要，以及各用途，各类型，各销售管道，各地区的趋势，及加入此市场的主要企业的简介等资讯。

目录

第1章 简介

第2章 调查手法

第3章 摘要整理

第4章 市场动态

  • 促进因素，阻碍因素，机会，课题的分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • COVID-19全球医疗用食品市场的影响

第5章 市场变数及预测

  • SWOT分析
  • PESTEL分析
  • 波特的五力分析
  • 热图分析

第6章 全球医疗用食品市场，各用途，2019年～2030年(100万美元)

  • 阿兹海默症
  • 糖尿病神经病变
  • 营养不足
  • ADHD
  • 其他

第7章 全球医疗用食品市场，各类型，2019年～2030年(100万美元)

  • 丸药
  • 粉末
  • 其他

第8章 全球医疗用食品市场，各销售管道，2019年～2030年(100万美元)

  • 零售
  • 线上销售
  • 机关销售

第9章 全球医疗用食品市场，各地区，2019年～2030年(100万美元)

  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 中东、非洲

第10章 企业简介

  • Abbott Laboratories
  • Cerecin Inc.
  • Danone
  • Fresenius SE & Co.
  • Meiji Holdings & Co. Ltd.
  • Metagenics Inc.
  • Nestle
  • Primus Pharmaceuticals Inc
  • Reckitt Benckiser Group
  • Targeted Medical Pharma Inc
简介目录
Product Code: HLCA2206

According to SPER Market Research, the Global Medical Foods Market is estimated to reach USD 34.32 billion by 2030 with a CAGR of 5.5%.

The medical foods market consists of sales of medical foods by entities (organizations, sole traders, and partnerships) that refer to foods, which are formulated to be administered or consumed under the presence of a physician, and it is intended to provide specific dietary management of a disease for which nutritional requirements are established by medical evaluation. Medical food pills are specially formulated to meet the nutritional requirements of patients with various medical conditions such as digression, ADHD, and others. They are used in the treatment of Alzheimer's disease, Diabetic Neuropathy, Nutritional Deficiency, ADHD, and others. As people get old, their dependency on certain nutritional foods increases especially medical foods to manage their health from chronic and age-related diseases.

The companies operating in the medical foods sector are developing innovative products with greater efficacy to cater to the demand from customers with specific niche diseases such as metabolic disorders, ADHD, and others.

Major players in the medical foods market are: Nestle, Fresenius Se & Co., Danone, Primus Pharmaceuticals Inc., Abbott Laboratories, Metagenics Inc., Targeted Medical Pharma Inc.

Impact of COVID-19 on the Global Medical Foods Market:

The report delivers insights on COVID-19 considering the changes in consumer behaviour and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments.

Scope of the report:

Report Metric Details

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030
  • Segments covered: By Application, By Type, By Sales Channel, By Region
  • Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa
  • Companies Covered: Abbott Laboratories, Cerecin Inc., Danone, Fresenius SE & Co., Meiji Holdings and Co. Ltd., Metagenics Inc., Nestle, Primus Pharmaceuticals Inc., Reckitt Benckiser Group, Targeted Medical Pharma Inc.

Global Medical Foods Market, By Application:

Based on the application, Global Medical Foods Market is segmented as; Alzheimer's Disease, Diabetic Neuropathy, Nutritional Deficiency, ADHD, Others.

Global Medical Foods Market, By Type:

Based on the type, Global Medical Foods Market is segmented as; Pills, Powder, Others.

Global Medical Foods Market, By Sales Channel:

Based on the sales channel, Global Medical Foods Market is segmented as; Retail Sales, Online Sales, Institutional Sales.

Global Medical Foods Market, By Region:

North America was the largest region in the medical foods market. Asia-Pacific is expected to be the fastest-growing region in the global medical foods market during the forecast period.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1. Secondary data
    • 2.1.2. Primary data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Medical Foods Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL analysis
    • 5.2.1. Political landscape
    • 5.2.2. Economic landscape
    • 5.2.3. Social landscape
    • 5.2.4. Technological landscape
    • 5.2.5. Environmental landscape
    • 5.2.6. Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of Buyers

5.3.3.Threat of Substitute

    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat map analysis

6. Global Medical Foods Market, By Application, 2019-2030 (USD Million)

  • 6.1. Alzheimer's Disease
  • 6.2. Diabetic Neuropathy
  • 6.3. Nutritional Deficiency
  • 6.4. ADHD
  • 6.5. Others

7. Global Medical Foods Market, By Type, 2019-2030 (USD Million)

  • 7.1. Pills
  • 7.2. Powder
  • 7.3. Others

8. Global Medical Foods Market, By Sales Channel, 2019-2030 (USD Million)

  • 8.1. Retail Sales
  • 8.2. Online Sales
  • 8.3. Institutional Sales

9. Global Medical Foods Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Cerecin Inc.
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. Danone
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. Fresenius SE & Co.
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Meiji Holdings & Co. Ltd.
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Metagenics Inc.
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Nestle
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Primus Pharmaceuticals Inc.
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Reckitt Benckiser Group
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Targeted Medical Pharma Inc.
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments